skip to Main Content

Stem Cell Therapeutics Merger, Technology Featured in Biotechnology Focus

Dr. Aaron Schimmer, University Health Network
Dr. Aaron Schimmer of the University Health Network discovered that Tigecycline was effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.

In a November 25 article in Biotechnology Focus magazine, author Shawn Lawrence highlights Stem Cell Therapeutics and Trillium Therapeutics Inc. coming together in a reverse merger that creates more opportunities to advance early-stage research.

The article profiles Dr. Aaron Schimmer and his discovery that Tigecycline is effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.

Here’s a quote from Lawrence’s article:

“Dr. Schimmer’s research is focused on drug repurposing – finding new indications for approved therapeutics. Focusing on established drugs with known safety profiles can significantly lower the risk in the drug development process, saving time and cost,” says Dr. Niclas Stiernholm, president and CEO of Stem Cell Therapeutics Corp.”

Continue Reading

Stem Cell Therapeutics licenses UHN’s Clinical Cancer Stem Cell Program

Stem Cell Therapeutics Corp. logo
Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.

The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.

This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.

The initial consideration of $1.6 million for the UHN License is to be satisfied by the issuance of 5,028,571 SCT common shares and 1,600,000 SCT common share purchase warrants to UHN and MaRS Innovation, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018.

Continue Reading

Biotechnology Focus’ December issue covers MaRS Innovation projects and partnerships

Stem Cell Therapeutics Corp. logo
Stem Cell Therapeutics Corp.

MaRS Innovation’s (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including:

Continue Reading
Back To Top